Seres Therapeutics Statistics
Total Valuation
MCRB has a market cap or net worth of $78.46 million. The enterprise value is $141.40 million.
Important Dates
The next estimated earnings date is Wednesday, May 7, 2025, before market open.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MCRB has 174.36 million shares outstanding. The number of shares has increased by 21.40% in one year.
| Current Share Class | 174.36M |
| Shares Outstanding | 174.36M |
| Shares Change (YoY) | +21.40% |
| Shares Change (QoQ) | +12.23% |
| Owned by Insiders (%) | 0.58% |
| Owned by Institutions (%) | 22.91% |
| Float | 128.45M |
Valuation Ratios
The trailing PE ratio is 531.54.
| PE Ratio | 531.54 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.80 |
| P/TBV Ratio | 5.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 1,039.71 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 6.65.
| Current Ratio | 0.94 |
| Quick Ratio | 0.80 |
| Debt / Equity | 6.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -30.43% |
| Return on Invested Capital (ROIC) | -58.47% |
| Return on Capital Employed (ROCE) | -123.05% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $1,320 |
| Employee Count | 103 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.43% in the last 52 weeks. The beta is 2.53, so MCRB's price volatility has been higher than the market average.
| Beta (5Y) | 2.53 |
| 52-Week Price Change | -29.43% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 32.99 |
| Average Volume (20 Days) | 1,057,003 |
Short Selling Information
The latest short interest is 16.01 million, so 9.18% of the outstanding shares have been sold short.
| Short Interest | 16.01M |
| Short Previous Month | 16.72M |
| Short % of Shares Out | 9.18% |
| Short % of Float | 12.46% |
| Short Ratio (days to cover) | 18.65 |
Income Statement
| Revenue | n/a |
| Gross Profit | -14.53M |
| Operating Income | -121.32M |
| Pretax Income | -82.68M |
| Net Income | 136,000 |
| EBITDA | -115.85M |
| EBIT | -121.32M |
| Earnings Per Share (EPS) | $0.00 |
Full Income StatementBalance Sheet
The company has $30.79 million in cash and $91.64 million in debt, giving a net cash position of -$60.85 million or -$0.35 per share.
| Cash & Cash Equivalents | 30.79M |
| Total Debt | 91.64M |
| Net Cash | -60.85M |
| Net Cash Per Share | -$0.35 |
| Equity (Book Value) | 13.78M |
| Book Value Per Share | 0.08 |
| Working Capital | -2.55M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$148.61 million and capital expenditures -$380,000, giving a free cash flow of -$148.99 million.
| Operating Cash Flow | -148.61M |
| Capital Expenditures | -380,000 |
| Free Cash Flow | -148.99M |
| FCF Per Share | -$0.85 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |